AbbVie Inc

More Details of AbbVie Inc Company

Company Info

Company codeABBV

Company nameAbbVie Inc

IPO dateJan 02, 2013

Founded at2012

CEOMr. Robert A. Michael, CPA

Number of employees55000

Security typeOrdinary Share

Fiscal year-endJan 02

Address1 N Waukegan Rd

CityNORTH CHICAGO

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code60064

Phone18479327900

Websitehttps://www.abbvie.com/

Company codeABBV

IPO dateJan 02, 2013

Founded at2012

Company Executives

Name

Name/Position

Position

Shareholding

Change

Mr. Richard A. Gonzalez

Executive Chairman of the Board

388.92K

-1.56%

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

221.98K

+10.69%

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

133.43K

+1.00%

Mr. Glenn Fletcher Tilton

Independent Director

50.71K

+2.68%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.27K

+16.14%

Mr. Edward J. (Ed) Rapp

Independent Director

41.74K

+3.27%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

37.25K

+3.68%

Dr. Robert J. Alpern, M.D.

Independent Director

34.44K

+3.99%

Mr. Frederick H. (Rick) Waddell

Independent Director

27.75K

+5.00%

Ms. Melody B. Meyer

Independent Director

15.29K

+9.46%

Name

Name/Position

Position

Shareholding

Change

Mr. Richard A. Gonzalez

Executive Chairman of the Board

388.92K

-1.56%

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

221.98K

+10.69%

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

133.43K

+1.00%

Mr. Glenn Fletcher Tilton

Independent Director

50.71K

+2.68%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.27K

+16.14%

Mr. Edward J. (Ed) Rapp

Independent Director

41.74K

+3.27%

Revenue Breakdown

Currency: USDUpdate time: Wed, Mar 5

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Immunology-SKYRIZI

11.71B

20.80%

Immunology-HUMIRA

8.99B

15.96%

Immunology-RINVOQ

5.97B

10.59%

Hematologic Oncology-IMBRUVICA

3.34B

5.94%

Neuroscience-Botox Therapeutic

3.28B

5.82%

Other

23.02B

40.86%

By RegionUSD

Name

Revenue

Proportion

United States

40.78B

72.38%

International

11.50B

20.42%

All other countries

3.03B

5.38%

Germany

1.46B

2.60%

Japan

1.12B

1.99%

Other

-1.57B

-2.78%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Immunology-SKYRIZI

11.71B

20.80%

Immunology-HUMIRA

8.99B

15.96%

Immunology-RINVOQ

5.97B

10.59%

Hematologic Oncology-IMBRUVICA

3.34B

5.94%

Neuroscience-Botox Therapeutic

3.28B

5.82%

Other

23.02B

40.86%

Shareholder

Update time: Fri, Feb 21

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

9.76%

BlackRock Institutional Trust Company, N.A.

5.10%

State Street Global Advisors (US)

4.51%

Geode Capital Management, L.L.C.

2.10%

Capital Research Global Investors

1.92%

Other

76.59%

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

9.76%

BlackRock Institutional Trust Company, N.A.

5.10%

State Street Global Advisors (US)

4.51%

Geode Capital Management, L.L.C.

2.10%

Capital Research Global Investors

1.92%

Other

76.59%

Type

Shareholder

Proportion

Investment Advisor

34.04%

Investment Advisor/Hedge Fund

29.85%

Research Firm

2.78%

Bank and Trust

2.23%

Pension Fund

2.22%

Sovereign Wealth Fund

1.52%

Insurance Company

0.63%

Hedge Fund

0.52%

Holding Company

0.39%

Other

25.79%

Institutional Shareholding

Update time: Thu, Feb 20

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

5107

1.31B

74.41%

+8.05M

2024Q4

5219

1.31B

74.47%

+8.91M

2024Q3

4974

1.29B

73.54%

-7.43M

2024Q2

4916

1.29B

73.53%

+2.26M

2024Q1

4930

1.28B

72.58%

-1.46M

2023Q4

4882

1.27B

72.31%

-1.48M

2023Q3

4694

1.26B

71.87%

-12.06M

2023Q2

4688

1.26B

71.51%

-30.41M

2023Q1

4658

1.26B

71.97%

-18.58M

2022Q4

4628

1.26B

71.69%

-10.54M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

172.30M

9.76%

+1.44M

+0.84%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

90.08M

5.1%

+893.97K

+1.00%

Dec 31, 2024

State Street Global Advisors (US)

79.62M

4.51%

+553.55K

+0.70%

Dec 31, 2024

Geode Capital Management, L.L.C.

37.14M

2.1%

+983.88K

+2.72%

Dec 31, 2024

Capital Research Global Investors

33.98M

1.92%

+778.12K

+2.34%

Dec 31, 2024

JP Morgan Asset Management

33.90M

1.92%

+881.82K

+2.67%

Dec 31, 2024

Capital International Investors

28.53M

1.61%

-8.25M

-22.43%

Dec 31, 2024

Charles Schwab Investment Management, Inc.

27.43M

1.55%

+3.59M

+15.09%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

25.09M

1.42%

+2.61M

+11.64%

Dec 31, 2024

Morgan Stanley Smith Barney LLC

22.68M

1.28%

+844.34K

+3.86%

Dec 31, 2024

Related ETFs

Update time: 21 hours ago

Name

Proportion

First Trust Morningstar Dividend Leaders Index Fund

8.4%

Federated Hermes MDT Large Cap Value ETF

6.7%

Health Care Select Sector SPDR Fund

6.52%

First Trust NASDAQ Pharmaceuticals ETF

6.38%

VanEck Pharmaceutical ETF

6.3%

Proshares Ultra Health Care

5.89%

iShares U.S. Healthcare ETF

5.69%

Goldman Sachs Future Health Care Equity ETF

5.19%

Fidelity MSCI Health Care Index ETF

5.12%

Direxion Daily Healthcare Bull 3X Shares

5.09%

First Trust Morningstar Dividend Leaders Index Fund

Proportion8.4%

Federated Hermes MDT Large Cap Value ETF

Proportion6.7%

Health Care Select Sector SPDR Fund

Proportion6.52%

First Trust NASDAQ Pharmaceuticals ETF

Proportion6.38%

VanEck Pharmaceutical ETF

Proportion6.3%

Proshares Ultra Health Care

Proportion5.89%

iShares U.S. Healthcare ETF

Proportion5.69%

Goldman Sachs Future Health Care Equity ETF

Proportion5.19%

Fidelity MSCI Health Care Index ETF

Proportion5.12%

Direxion Daily Healthcare Bull 3X Shares

Proportion5.09%

Dividend

A total of 48.58B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 06, 2024

ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 21, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 15, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Oct 27, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option

Jan 16, 2024

Feb 15, 2024

Jan 12, 2024

Sep 11, 2023

ABBV.NB Final Cash Dividend of gross USD 1.48 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option

Oct 13, 2023

Nov 15, 2023

Oct 12, 2023

Jun 22, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option

Jul 14, 2023

Aug 15, 2023

Jul 13, 2023

Feb 16, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option

Apr 14, 2023

May 15, 2023

Apr 13, 2023

Oct 28, 2022

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option

Jan 13, 2023

Feb 15, 2023

Jan 12, 2023

Sep 09, 2022

ABBV.NB Final Cash Dividend of gross USD 1.41 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option

Oct 14, 2022

Nov 15, 2022

Oct 13, 2022

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

211.540USD

AbbVie Inc

211.540

Overview

Company